



Liste des publications IUCT-O/CRCT

Mars 2022

1. Apalla, Z., Nikolaou, V., Fattore, D., Fabbrocini, G., Freites-Martinez, A., Sollena, P., Lacouture, M., Kraehenbuehl, L., Stratigos, A., Peris, K., Lazaridou, E., Richert, B., Vigarios, E., Riganti, J., Baroudjian, B., Filoni, A., Dodiuk-Gad, R., Lebbé, C., & Sibaud, V. (2022). **European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement.** *Journal of the European Academy of Dermatology and Venereology : JEADV*, 36(3), 332–350. (IF : 6,166. CAT : A) <https://doi.org/10.1111/jdv.17855>
2. Appay, R., Bielle, F., Sievers, P., Baret, D., Fina, F., Boutonnat, J., Adam, C., Gauchotte, G., Godfraind, C., Lhermitte, B., Maurage, C. A., Meyronet, D., Mokhtari, K., Rousseau, A., Tauziède-Espariat, A., Tortel, M. C., Uro-Coste, E., Burel-Vandenbos, F., Chotard, G., Pesce, F., ... Figarella-Branger, D. (2022). **Rosette-forming glioneuronal tumours are midline, FGFR1-mutated tumours.** *Neuropathology and applied neurobiology*, e12813. Advance online publication. (IF : 8,09. CAT : A) <https://doi.org/10.1111/nan.12813>
3. Arlet, J. B., Lionnet, F., Khimoud, D., Joseph, L., de Montalembert, M., Morisset, S., Garou, A., Cannas, G., Cougoul, P., Guittou, C., Holvoet, L., Odièvre, M. H., Cheminet, G., Bartolucci, P., Santin, A., Bernit, E., de Luna, G., & DREPANO COVID-19 Collaborative Group (2022). **Risk factors for severe COVID-19 in hospitalized sickle cell disease patients: A study of 319 patients in France.** *American journal of hematology*, 97(3), E86–E91. (IF : 10,047. CAT : A) <https://doi.org/10.1002/ajh.26432>
4. Babin, L., Darchen, A., Robert, E., Aid, Z., Borry, R., Soudais, C., Piganeau, M., De Cian, A., Giovannangeli, C., Bawa, O., Rigaud, C., Scoazec, J. Y., Couronné, L., Veleau, L., Cieslak, A., Asnafi, V., Sibon, D., Lamant, L., Meggetto, F., Mercher, T., ... Brunet, E. (2022). **De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells.** *Molecular cancer*, 21(1), 65. (IF : 27,401. CAT : A) <https://doi.org/10.1186/s12943-022-01520-0>
5. Bakavicius, A., Marra, G., Macek, P., Robertson, C., Abreu, A. L., George, A. K., Malavaud, B., Coloby, P., Rischmann, P., Moschini, M., Rastinehad, A. R., Sidana, A., Stabile, A., Tourinho-Barbosa, R., de la Rosette, J., Ahmed, H., Polascik, T., Cathelineau, X., & Sanchez-Salas, R. (2022). **Available evidence on HIFU for focal treatment of prostate cancer: a systematic review.** *International braz j urol : official journal of the*

Brazilian Society of Urology, 48(2), 263–274. (IF : 1,541. CAT : E)

<https://doi.org/10.1590/S1677-5538.IBJU.2021.0091>

6. Baron, M., Soulié, C., Lavalé, A., Assoumou, L., Abbar, B., Fouquet, B., Rousseau, A., Veyri, M., Samri, A., Makinson, A., Choquet, S., Mazières, J., Brosseau, S., Autran, B., Costagliola, D., Katlama, C., Cadranel, J., Marcelin, A. G., Lambotte, O., Spano, J. P., ... The Anrs Co OncoVIHAC Study Group (2022). **Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer.** *Cells*, 11(6), 1015. (IF : 6,6. CAT : C)
<https://doi.org/10.3390/cells11061015>
7. Battistella, M., Balme, B., Jullie, M. L., Zimmermann, U., Carlotti, A., Crinquette, M., Frouin, E., Macagno, N., Ortonne, N., Lamant, L., de la Fouchardiere, A., Aubriot-Lorton, M. H., Durand, L., Josselin, N., Franck, F., Chatelain, D., Lemasson, G., Algros, M. P., Durlach, A., Machet, M. C., ... CARADERM network (2022). **Impact of expert pathology review in skin adnexal carcinoma diagnosis: Analysis of 2573 patients from the French CARADERM network.** *European journal of cancer (Oxford, England : 1990)*, 163, 211–221. (IF : 9,152. CAT : B) <https://doi.org/10.1016/j.ejca.2021.11.027>
8. Baudou, E., Pariente, J., Péran, P., Tensaouti, F., Pollidoro, L., Meligne, D., Ducassou, A., Gros-Dagnac, H., Arribarat, G., Desirat, J. P., Bertozzi, A. I., Gambart, M., Larrieu-Ciron, D., Barbolosi, D., Muracciole, X., Lemesle, B., Sevely, A., Roques, M., Cazaux, M., Tallet, J., ... Laprie, A. (2021). **A prospective behavioral and imaging study exploring the impact on long-term memory of radiotherapy delivered for a brain tumor in childhood and adolescence.** *Clinical and translational radiation oncology*, 33, 7–14. (IF : NC. CAT : NC) <https://doi.org/10.1016/j.ctro.2021.10.006>
9. Bellien, J., Bozec, E., Bounoure, F., Khettab, H., Malloizel-Delaunay, J., Skiba, M., Iacob, M., Donnadiou, N., Coquard, A., Morio, B., Laillet, B., Rigaudière, J. P., Chardigny, J. M., Monteil, C., Vendeville, C., Mercier, A., Cailleux, A. F., Blanchard, A., Amar, J., Fezeu, L. K., ... Joannidès, R. (2022). **The effect of camelina oil on vascular function in essential hypertensive patients with metabolic syndrome: a randomized, placebo-controlled, double-blind study.** *The American journal of clinical nutrition*, 115(3), 694–704. (IF : 7,045. CAT : B) <https://doi.org/10.1093/ajcn/nqab374>
10. Bobin, A., Kyheng, M., Guidez, S., Gruchet-Merouze, C., Richez, V., Duhamel, A., Karlin, L., Kolb, B., Tiab, M., Araujo, C., Meuleman, N., Malfuson, J. V., Bourquard, P., Lenain, P., Perrot, A., Roussel, M., Jaccard, A., Petillon, M. O., Belhadj-Merzoug, K., Chretien, M. L., ... Leleu, X. (2022). **Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.** *Leukemia*, 36(3), 881–884. (IF : 11,528. CAT : A)
<https://doi.org/10.1038/s41375-021-01415-x>
11. Boudou-Rouquette, P., Martin, E., Kempf, E., Penel, N., Toulmonde, M., Bompas, E., Duffaud, F., Firmin, N., Bertucci, F., Kurtz, J. E., Chaigneau, L., Isambert, N., Saada-Bouazid, E., Dubray-Longeras, P., Larousserie, F., Anract, P., Chevreau, C., Blay, J. Y., Piperno-Neumann, S., & GSF-GETO, ResOs and NETSARC+ (2022). **Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group.** *International journal of cancer*, 150(5), 825–836. (IF : 7,396. CAT : B)
<https://doi.org/10.1002/ijc.33837>

12. Campana, F., Lan, R., Girard, C., Rochefort, J., Le Pelletier, F., Leroux-Villet, C., Mares, S., Millot, S., Zlowodzki, A. S., Sibaud, V., Tessier, M. H., Vaillant, L., Fricain, J. C., & Samimi, M. (2022). **French guidelines for the management of oral lichen planus (excluding pharmacological therapy)**. *Annales de dermatologie et de venerologie*, 149(1), 14–27. (IF : 0,777. CAT : E) <https://doi.org/10.1016/j.annder.2021.04.003>
13. Classe, J. M., Ferron, G., Ouldamer, L., Gauthier, T., Emambux, S., Gladieff, L., Dupre, P. F., & Anota, A. (2022). **CHRONO: randomized trial of the CHRONology of surgery after Neoadjuvant chemotherapy for Ovarian cancer**. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*, ijgc-2021-003320. Advance online publication. (IF : 3,437. CAT : C) <https://doi.org/10.1136/ijgc-2021-003320>
14. Clichet, V., Harrivel, V., Delette, C., Guiheneuf, E., Gautier, M., Morel, P., Assouan, D., Merlusca, L., Beaumont, M., Lebon, D., Caulier, A., Marolleau, J. P., Matthes, T., Vergez, F., Garçon, L., & Boyer, T. (2022). **Accurate classification of plasma cell dyscrasias is achieved by combining artificial intelligence and flow cytometry**. *British journal of haematology*, 196(5), 1175–1183. (IF : 6,998. CAT : B) <https://doi.org/10.1111/bjh.17933>
15. Conte, C., Vayr, F., Pajiep, M. C., Despas, F., Huguet, F., Mestre, M. L., Gauthier, M., & Herin, F. (2022). **Impact of the treatment of chronic myeloid leukaemia by tyrosine-kinase inhibitors on sick leaves refund: a nationwide cohort study**. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*, 10.1007/s00520-022-06968-w. Advance online publication. (IF : 3,603. CAT : B) <https://doi.org/10.1007/s00520-022-06968-w>
16. Daix, M., Martinez Gomez, C., Angeles, M. A., Tock, S., Gladieff, L., Gabiache, E., Mery, E., Martinez, A., Cibula, D., & Ferron, G. (2022). **Extended pelvic resection for gynecological malignancies: A review of out-of-the-box surgery**. *Gynecologic oncology*, S0090-8258(22)00174-3. Advance online publication. (IF : 5,482. CAT : A) <https://doi.org/10.1016/j.ygyno.2022.03.002>
17. Dalenc, F., Lusque, A., De La Motte Rouge, T., Pistilli, B., Brain, E., Pasquier, D., Debled, M., Thery, J. C., Gonçalves, A., Desmoulins, I., Levy, C., Uwer, L., Ferrero, J. M., Eymard, J. C., Mouret-Reynier, M. A., Patsouris, A., Frenel, J. S., Petit, T., Chevrot, M., Bachelot, T., ... Guiu, S. (2022). **Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study**. *European journal of cancer (Oxford, England : 1990)*, 164, 70–79. (IF : 9,162. CAT : B) <https://doi.org/10.1016/j.ejca.2021.12.031>
18. Darmon-Novello, M., Adam, J., Lamant, L., Battistella, M., Ortonne, N., Balme, B., de la Fouchardière, A., Chaltiel, L., Gerard, E., Franchet, C., & Vergier, B. (2022). **Harmonization of PD-L1 immunohistochemistry and mRNA expression scoring in metastatic melanoma: a multicenter analysis**. *Histopathology*, 10.1111/his.14651. Advance online publication. (IF : 5,087. CAT : B) <https://doi.org/10.1111/his.14651>
19. Delafoy, M., Verschuur, A., Scheleirmacher, G., Tabone, M. D., Sudour-Bonnange, H., Thébaud, E., Freycon, C., Notz-Carrère, A., Boulanger, C., Pellier, I., Irtan, S., Muracciole, X., Coulomb-L'Hermine, A., Dijoud, F., Morelle, M., Bergeron, C., & Pasqualini, C. (2022). **High-dose chemotherapy followed by autologous stem cell rescue in**

- Wilms tumors: French report on toxicity and efficacy.** *Pediatric blood & cancer*, 69(3), e29431. (IF : 3,167. CAT : B) <https://doi.org/10.1002/pbc.29431>
20. Delaloge, S., Dureau, S., D'Hondt, V., Desmoulins, I., Heudel, P. E., Duhoux, F. P., Levy, C., Lerebours, F., Mouret-Reynier, M. A., Dalenc, F., Frenel, J. S., Jouannaud, C., Venat-Bouvet, L., Nguyen, S., Callens, C., Gentien, D., Rapinat, A., Manduzio, H., Vincent-Salomon, A., Lemonnier, J., ... French Breast cancer Intergroup Unicancer-UCBG (2022). **Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer.** *European journal of cancer (Oxford, England : 1990)*, S0959-8049(22)00035-1. Advance online publication. (IF : 9,162. CAT : B) <https://doi.org/10.1016/j.ejca.2022.01.014>
 21. Deshors, P., Arnauduc, F., Boëlle, B., Cohen-Jonathan Moyal, E., Courtade-Saïdi, M., & Evrard, S. M. (2022). **Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells.** *Cancers*, 14(6), 1551. (IF : 6,639. CAT : B) <https://doi.org/10.3390/cancers14061551>
 22. Devillier, R., Forcade, E., Garnier, A., Guenounou, S., Thepot, S., Guillermin, G., Ceballos, P., Hicheri, Y., Dumas, P. Y., Peterlin, P., Hunault-Berger, M., Béné, M. C., Bouvier, A., Chevallier, P., Blaise, D., Vey, N., Pigneux, A., Récher, C., & Huynh, A. (2022). **In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study.** *Blood advances*, 6(6), 1804–1812. (IF : 6,686. CAT : B) <https://doi.org/10.1182/bloodadvances.2021004435>
 23. Di Carlo, V., Stiller, C. A., Eisemann, N., Bordoni, A., Matz, M., Curado, M. P., Daubisse-Marliac, L., Valkov, M., Bulliard, J. L., Morrison, D., Johnson, C., Girardi, F., Marcos-Gragera, R., Škerija, M., Larønningen, S., Sirri, E., Coleman, M. P., Allemani, C., & CONCORD Working Group (2022). **Does the morphology of cutaneous melanoma help explain the international differences in survival? Results from 1,578,482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3).** *The British journal of dermatology*, 10.1111/bjd.21274. Advance online publication. (IF : 9,302. CAT : A) <https://doi.org/10.1111/bjd.21274>
 24. Dubucs, C., Groussolles, M., Ousselin, J., Sartor, A., Van Acker, N., Vayssière, C., Pasquier, C., Reyre, J., Batlle, L., Favarel Clinical Research Associate, S., Duchanois Midwife, D., Jauffret Clinical Research Associate, V., Courtade-Saïdi, M., & Aziza, J. (2022). **Severe placental lesions due to maternal SARS-CoV-2 infection associated to intrauterine fetal death.** *Human pathology*, 121, 46–55. (IF : 3,466. CAT : C) <https://doi.org/10.1016/j.humpath.2021.12.012>
 25. Durot, E., Kanagaratnam, L., Zanwar, S., Toussaint, E., Kastiris, E., D'Sa, S., Alcoceba, M., Tomowiak, C., Hivert, B., Protin, C., Abeykoon, J. P., Vos, J., Michallet, A. S., Rodier, C., Dupuis, J., Leprêtre, S., Merabet, F., Roussel, X., Zini, J. M., Regny, C., ... Delmer, A. J. (2022). **High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia.** *Blood advances*, bloodadvances.2022007331. Advance online publication. (IF : 6,686. CAT : B) <https://doi.org/10.1182/bloodadvances.2022007331>
 26. Grand, A., Desbougues, J. B., Guillemot, C., Spinau, C., & Puisset, F. (2022). **Still Some Constraints Before Generalization of Remote Clinical Trial Monitoring: A**

Pharmacist's Point of View of the Lessons From the COVID-19 Pandemic. *JCO oncology practice*, 18(3), 242–243. (IF : 3,84. CAT : D)
<https://doi.org/10.1200/OP.21.00749>

27. Hofste Op Bruinink, D., Kuiper, R., van Duin, M., Cupedo, T., van der Velden, V., Hoogenboezem, R., van der Holt, B., Beverloo, H. B., Valent, E. T., Vermeulen, M., Gay, F., Broijl, A., Avet-Loiseau, H., Munshi, N. C., Musto, P., Moreau, P., Zweegman, S., van de Donk, N., & Sonneveld, P. (2022). **Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, JCO2101217. Advance online publication. (IF : 44,544. CAT : A)
<https://doi.org/10.1200/JCO.21.01217>
28. Icard, C., Mocquot, P., Nogaro, J. C., Despas, F., & Gauthier, M. (2022). **Lenalidomide-induced arthritis: A case report and review of literature and pharmacovigilance databases.** *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*, 28(2), 453–456. (IF : 1,809. CAT : E) <https://doi.org/10.1177/10781552211038001>
29. Ingen-Housz-Oro, S., Milpied, B., Badrignans, M., Carrera, C., Elshot, Y. S., Bensaid, B., Segura, S., Apalla, Z., Markova, A., Staumont-Sallé, D., Marti-Marti, I., Giavedoni, P., Chua, S. L., Darrigade, A. S., Dezoteux, F., Starace, M., Torre, A. C., Riganti, J., de Prost, N., Lebrun-Vignes, B., ... Sibaud, V. (2022). **Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases.** *Melanoma research*, 10.1097/CMR.0000000000000819. Advance online publication. (IF : 3,599. CAT : C) <https://doi.org/10.1097/CMR.0000000000000819>
30. JaffreLOT, M., Farés, N., Brunac, A. C., Laurenty, A. P., Danjoux, M., Grand, D., Icher, S., Meilleroux, J., Mery, E., Buscail, E., Maulat, C., Toulas, C., Vande Perre, P., Chipoulet, E., Bonnet, D., Staub, A., Guimbaud, R., & Selves, J. (2022). **An unusual phenotype occurs in 15% of mismatch repair-deficient tumors and is associated with non-colorectal cancers and genetic syndromes.** *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*, 35(3), 427–437. (IF : 7,842. CAT : A) <https://doi.org/10.1038/s41379-021-00918-3>
31. Jaouen, F., Tessier, M. H., Vaillant, L., Azib-Meftah, S., Misery, L., Bénétou, N., Delaporte, E., Kaddour, A., Ingen-Housz-Oro, S., Nahon, S., Masson-Regnault, M., Sibaud, V., Fricain, J. C., Bessis, D., Girard, C., & Samimi, M. (2022). **Response to systemic therapies in granulomatous cheilitis: Retrospective multicenter series of 61 patients.** *Journal of the American Academy of Dermatology*, 86(3), 667–669. (IF : 11,527. CAT : A) <https://doi.org/10.1016/j.jaad.2021.02.047>
32. Jooste, V., Bengrine-Lefevre, L., Manfredi, S., Quipourt, V., Grosclaude, P., Facy, O., Lepage, C., Ghiringhelli, F., & Bouvier, A. M. (2022). **Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice.** *Cancers*, 14(7), 1675. (IF : 6,639. CAT : B) <https://doi.org/10.3390/cancers14071675>
33. Kayal, G., Chauvin, M., Mora-Ramirez, E., Clayton, N., Vergara-Gil, A., Tran-Gia, J., Lassmann, M., Calvert, N., Tipping, J., Struelens, L., MRTDosimetry Collaboration, & Bardiès, M. (2022). **Modelling SPECT auto-contouring acquisitions for ¹⁷⁷Lu & ¹³¹I molecular radiotherapy using new developments in Geant4/GATE.** *Physica medica*

: *PM* : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB), 96, 101–113. (IF : 2,685. CAT : D) <https://doi.org/10.1016/j.ejmp.2022.03.003>

34. Kayal, G., Clayton, N., Vergara-Gil, A., Struelens, L., & Bardiès, M. (2022). **Proof-of-concept of DosiTest: A virtual multicentric clinical trial for assessing uncertainties in molecular radiotherapy dosimetry.** *Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)*, 97, 25–35. Advance online publication. (IF : 2,685. CAT : D) <https://doi.org/10.1016/j.ejmp.2022.03.011>
35. Kervarrec, T., Pissaloux, D., Poilane, J., Tirode, F., Tallet, A., Collin, C., Tallegas, M., Berthon, P., Gaboriaud, P., Sohier, P., Calonje, E., Luzar, B., Goto, K., Cokelaere, K., Lamant, L., Balme, B., Wild, R., Neuville, A., Deschamps, L., Auberger, E., ... Jullie, M. L. (2022). **Recurrent FOXK1::GRHL and GPS2::GRHL fusions in trichogerminoma.** *The Journal of pathology*, 257(1), 96–108. (IF : 7,996. CAT : A) <https://doi.org/10.1002/path.5872>
36. König, F., Grossmann, N. C., Soria, F., D'Andrea, D., Juvet, T., Potretzke, A., Djaladat, H., Ghoreifi, A., Kikuchi, E., Hayakawa, N., Mari, A., Khene, Z. E., Fujita, K., Raman, J. D., Breda, A., Fontana, M., Sfakianos, J. P., Pfail, J. L., Laukhtina, E., Rajwa, P., ... Pradere, B. (2022). **Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics.** *Cancers*, 14(7), 1781. (IF : 6,639. CAT : B) <https://doi.org/10.3390/cancers14071781>
37. Lapierre, A., Hennequin, C., Beneux, A., Belhomme, S., Benziane Ouaritini, N., Biston, M. C., Crehange, G., de Crevoisier, R., Dumas, J. L., Fawzi, M., Lisbona, A., Pasquier, D., Pelissier, S., Graff-Cailleaud, P., Pommier, P., Sargos, P., Simon, J. M., Supiot, S., Tantot, F., & Chapet, O. (2022). **Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group.** *Critical reviews in oncology/hematology*, 173, 103661. Advance online publication. (IF : 6,312. CAT : B) <https://doi.org/10.1016/j.critrevonc.2022.103661>
38. Lapierre, L., Syrykh, C., Largeaud, L., Cabarrou, B., Filleron, T., Oberic, L., Kanoun, S., Coster, L., Laurent, C., Branco, B., Gadaud, N., Récher, C., Brechemier, D., Balardy, L., Vergez, F., Ysebaert, L., & Gauthier, M. (2022). **"Accelerated phase" chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies.** *Hematological oncology*, 10.1002/hon.2985. Advance online publication. (IF : 5,271. CAT : C) <https://doi.org/10.1002/hon.2985>
39. Leboulleux, S., Bornaoud, C., Chougnet, C. N., Zerdoud, S., Al Ghuzlan, A., Catargi, B., Do Cao, C., Kelly, A., Barge, M. L., Lacroix, L., Dygai, I., Vera, P., Rusu, D., Schneegans, O., Benisvy, D., Klein, M., Roux, J., Eberle, M. C., Bastie, D., Nascimento, C., ... Borget, I. (2022). **Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer.** *The New England journal of medicine*, 386(10), 923–932. (IF : 91,245. CAT : A+) <https://doi.org/10.1056/NEJMoa2111953>
40. Lebre, T., Pignot, G., Colombel, M., Guy, L., Rebillard, X., Savareux, L., Roumigue, M., Nivet, S., Coutade Saidi, M., Piaton, E., & Radulescu, C. (2022). **Artificial intelligence**

to improve cytology performances in bladder carcinoma detection: results of the VisioCyt test. *BJU international*, 129(3), 356–363. (IF : 5,588. CAT : B)

<https://doi.org/10.1111/bju.15382>

41. Lechien, J. R., Chiesa-Estomba, C. M., Cabaraux, P., Mat, Q., Huet, K., Harmegnies, B., Horoi, M., Le Bon, S. D., Rodriguez, A., Dequanter, D., Hans, S., Crevier-Buchman, L., Hochet, B., Distinguin, L., Chekkoury-Idrissi, Y., Ciciu, M., El Afia, F., Barillari, M. R., Cammaroto, G., Fakhry, N., ... Saussez, S. (2022). **Features of Mild-to-Moderate COVID-19 Patients With Dysphonia.** *Journal of voice : official journal of the Voice Foundation*, 36(2), 249–255. (IF : 2,009. CAT : D)
<https://doi.org/10.1016/j.jvoice.2020.05.012>
42. Leveque, E., Rouch, A., Syrykh, C., Mazières, J., Brouchet, L., Valitutti, S., Espinosa, E., & Lafouresse, F. (2022). **Phenotypic and Histological Distribution Analysis Identify Mast Cell Heterogeneity in Non-Small Cell Lung Cancer.** *Cancers*, 14(6), 1394. (IF : 6,639. CAT : B) <https://doi.org/10.3390/cancers14061394>
43. Maillard, M., Louveau, B., Vilquin, P., Goldwirt, L., Thomas, F., & Mourah, S. (2022). **Pharmacogenomics in solid cancers and hematologic malignancies: Improving personalized drug prescription.** *Thérapie*, 77(2), 171–183. (IF : 2,07. CAT : E)
<https://doi.org/10.1016/j.therap.2021.11.003>
44. Manson, G., Lemchukwu, A. C., Mokrane, F. Z., Lopci, E., Aide, N., Vercellino, L., Houot, R., & Dercle, L. (2022). **Interpretation of 2-[¹⁸F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors.** *European radiology*, 10.1007/s00330-022-08669-8. Advance online publication. (IF : 5,315. CAT : B)
<https://doi.org/10.1007/s00330-022-08669-8>
45. Marchais, A., Marques da Costa, M. E., Job, B., Abbas, R., Drubay, D., Piperno-Neumann, S., Fromigué, O., Gomez-Brouchet, A., Redini, F., Droit, R., Lervat, C., Entze-Werle, N., Pacquement, H., Devoldere, C., Cupissol, D., Bodet, D., Gandemer, V., Berger, M., Marec-Berard, P., Jimenez, M., ... Gaspar, N. (2022). **Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis.** *Cancer research*, 82(6), 974–985. (IF : 12,701. CAT : A) <https://doi.org/10.1158/0008-5472.CAN-20-4189>
46. Martini, A., Lonati, C., Necchi, A., Galsky, M. D., Ploussard, G., Fallara, G., Pellegrino, A., Simeone, C., Suardi, N., Zamboni, S., Krajewski, W., Simone, G., Briganti, A., Montorsi, F., Mattei, A., Shariat, S. F., Moschini, M., & European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. (2022). **Metastasis Within Three Years from Radical Nephroureterectomy as a Potential Surrogate for Overall Survival.** *Clinical genitourinary cancer*, S1558-7673(22)00051-9. Advance online publication. (IF : 2,872. CAT : D)
<https://doi.org/10.1016/j.clgc.2022.03.007>
47. Mateos, M. V., Weisel, K., De Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., Cavo, M., Vij, R., Lindsey-Hill, J., Dytfeld, D., Angelucci, E., Perrot, A., Benjamin, R., van de Donk, N., Ocio, E. M., Scheid, C., Gay, F., Roeloffzen, W., Rodriguez-Otero, P., Broijl, A., ... Moreau, P. (2022). **LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.** *Leukemia*, 10.1038/s41375-022-

01531-2. Advance online publication. (IF : 11,528. CAT : A)

<https://doi.org/10.1038/s41375-022-01531-2>

48. Mertens, L. S., Claps, F., Mayr, R., Bostrom, P. J., Shariat, S. F., Zwarthoff, E. C., Boormans, J. L., Abas, C., van Leenders, G., Götz, S., Hippe, K., Bertz, S., Neuzillet, Y., Sanders, J., Broeks, A., Peters, D., van der Heijden, M. S., Jewett, M., Stöhr, R., Zlotta, A. R., ... van Rhijn, B. (2022). **Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.** *Urologic oncology*, 40(3), 110.e1–110.e9. (IF : 3,498. CAT : C) <https://doi.org/10.1016/j.urolonc.2021.10.010>
49. Moinard-Butot, F., Saint-Martin, C., Pflumio, C., Carton, M., Jacot, W., Cottu, P. H., Diéras, V., Dalenc, F., Goncalves, A., Debled, M., Patsouris, A., Mouret-Reynier, M. A., Vanlemmens, L., Leheurteur, M., Emile, G., Ferrero, J. M., Desmoulins, I., Uwer, L., Eymard, J. C., Cheaib, B., ... Petit, T. (2022). **Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.** *Breast (Edinburgh, Scotland)*, 63, 54–60. Advance online publication. (IF : 4,38. CAT : B) <https://doi.org/10.1016/j.breast.2022.03.004>
50. Nazon, C., Pierrelvein, M., Willaume, T., Lhermitte, B., Weingertner, N., Marco, A. D., Bund, L., Vincent, F., Bierry, G., Gomez-Brouchet, A., Redini, F., Gaspar, N., Dontenwill, M., & Entz-Werle, N. (2022). **Together Intra-Tumor Hypoxia and Macrophagic Immunity Are Driven Worst Outcome in Pediatric High-Grade Osteosarcomas.** *Cancers*, 14(6), 1482. (IF : 6,639. CAT : B) <https://doi.org/10.3390/cancers14061482>
51. Passet, M., Kim, R., Gachet, S., Sigaux, F., Chaumeil, J., Galland, A., Sexton, T., Quentin, S., Hernandez, L., Larcher, L., Bergugnat, H., Ye, T., Karasu, N., Caye-Eude, A., Heizmann, B., Duluc, I., Chevallier, P., Rousselot, P., Huguet, F., Leguay, T. T., ... Clappier, E. (2022). **Concurrent CDX2 cis-deregulation and UBTF-ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL.** *Blood*, blood.2021014723. Advance online publication. (IF : 22,113. CAT : A) <https://doi.org/10.1182/blood.2021014723>
52. Pfister, C., Gravis, G., Fléchon, A., Chevreau, C., Mahammedi, H., Laguerre, B., Guillot, A., Joly, F., Soulié, M., Allory, Y., Harter, V., Culine, S., & VESPER Trial Investigators (2022). **Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, JCO2102051. Advance online publication. (IF : 44,544. CAT : A) <https://doi.org/10.1200/JCO.21.02051>
53. Pratz, K. W., Jonas, B. A., Pullarkat, V., Recher, C., Schuh, A. C., Thirman, M. J., Garcia, J. S., DiNardo, C. D., Vorobyev, V., Fracchiolla, N. S., Yeh, S. P., Jang, J. H., Ozcan, M., Yamamoto, K., Illes, A., Zhou, Y., Dail, M., Chyla, B., Potluri, J., & Döhner, H. (2022). **Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 40(8), 855–865. (IF : 44,544. CAT : A) <https://doi.org/10.1200/JCO.21.01546>

54. Sibaud, V., Brun, A., Meyer, N., Oberic, L., Lamant, L., & Ysebaert, L. (2022). **Efficacy of dupilumab in eosinophilic dermatosis of haematologic malignancy (EDHM) needs to be confirmed.** *Journal of the European Academy of Dermatology and Venereology : JEADV*, 36(3), e213–e215. (IF : 6,166. CAT : A) <https://doi.org/10.1111/jdv.17748>
55. Sokal, A., de Nadaï, T., Maquet, J., Comont, T., Limal, N., Michel, M., Beyne-Rauzy, O., Godeau, B., Adoue, D., Mahévas, M., Moulis, G., & CARMEN investigators group (2022). **Primary immune thrombocytopenia in very elderly patients: particularities in presentation and management: results from the prospective CARMEN-France Registry.** *British journal of haematology*, 196(5), 1262–1270. (IF : 6,998. CAT : B) <https://doi.org/10.1111/bjh.17935>
56. Sonpavde, G. P., Sternberg, C. N., Lorient, Y., Marabelle, A., Lee, J. L., Fléchon, A., Roubaud, G., Pouessel, D., Zagonel, V., Calabro, F., Banna, G. L., Shin, S. J., Vera-Badillo, F. E., Powles, T., Hellmis, E., Miranda, P., Lima, A. R., Emeribe, U., Oh, S. M., & Hotte, S. J. (2022). **Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.** *European journal of cancer (Oxford, England : 1990)*, 163, 55–65. (IF : 9,162. CAT : B) <https://doi.org/10.1016/j.ejca.2021.12.012>
57. Strumia, M., Perrin, M. L., Patras de Compaigno, E., Conte, C., Montastruc, F., Lapeyre-Mestre, M., Sibaud, V., & Despas, F. (2022). **Dermatological adverse drug reactions of anticancer drugs: International data of pharmacovigilance: VigiBase®.** *Thérapie*, 77(2), 219–227. (IF : 2,07. CAT : E) <https://doi.org/10.1016/j.therap.2021.12.006>
58. Talmont, F., Mitri, E., Dozier, C., Besson, A., Cuvillier, O., & Hatzoglou, A. (2022). **Sphingosine 1-Phosphate Receptor 5 (S1P5) Deficiency Promotes Proliferation and Immortalization of Mouse Embryonic Fibroblasts.** *Cancers*, 14(7), 1661. (IF : 6,639. CAT : B) <https://doi.org/10.3390/cancers14071661>
59. Tsaor, I., van den Bergh, R., Soeterik, T., Thomas, A., Brandt, M. P., Zattoni, F., Dal Moro, F., Morlacco, A., Collavino, J., Ploussard, G., Surcel, C., Mirvald, C., Carmona, O., Rosenzweig, B., Ruckes, C., Heisinger, T., Heidegger, I., Gandaglia, G., Dotzauer, R., & European Association of Urology Young Academic Urologists Prostate Cancer Working Party (2022). **Predictors of Unfavorable Pathology in Patients with Incidental (pT1a-T1b) Prostate Cancer.** *European urology focus*, S2405-4569(22)00063-3. Advance online publication. (IF : 5,996. CAT : B) <https://doi.org/10.1016/j.euf.2022.03.009>
60. Veiga, D., Tremblay, M., Gerby, B., Herblot, S., Haman, A., Gendron, P., Lemieux, S., Zúñiga-Pflücker, J. C., Hébert, J., Cohen, J. P., & Hoang, T. (2022). **Monoallelic *Heb/Tcf12* Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.** *Frontiers in immunology*, 13, 867443. (IF : 7,561. CAT : B) <https://doi.org/10.3389/fimmu.2022.867443>
61. Vergnolle, I., Douat-Beyries, C., Boulinguez, S., Rieu, J. B., Vial, J. P., Baracou, R., Boudot, S., Cazeneuve, A., Chaugne, S., Durand, M., Estival, S., Lablanche, N., Nicolau-Travers, M. L., Tournier, E., Lamant, L., & Vergez, F. (2022). **CD158k and PD-1 expressions**

define heterogeneous subtypes of Sezary syndrome. *Blood advances*, 6(6), 1813–1825. (IF : 6,686. CAT : B) <https://doi.org/10.1182/bloodadvances.2021005147>

